

Special Issue

Cancer Targeted Gene and Drug Delivery Nanosystems

Message from the Guest Editor

Nanotechnology-based systems have shown that they can greatly contribute to the development of novel and successful antitumor strategies, offering higher therapeutic efficacy and fewer side effects than conventional approaches. In fact, targeted nanosystems, have the ability to both passively (in the case of solid tumors) and actively accumulate in tumors, due to the enhanced permeation and retention (EPR) effect and the incorporation of target moieties in nanocarriers, respectively. Thus, targeted nanosystems may allow the specific delivery of therapeutic agents in target cells, avoiding their release in the non-target ones. Moreover, nanosystems facilitate the development of innovative multitarget therapeutic strategies in a single nanoplatform, allowing the specific and simultaneous delivery of different therapeutic agents in target cells, increasing antitumor efficiency and reducing secondary effects. This Special Issue aims to highlight the recent developments in cancer-targeted genes and drug delivery nanosystems. Original papers or reviews on the design, development, characterization, and application of drug and/or gene delivery nanosystems are welcome.

Guest Editor

Dr. Henrique Faneca

Center for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal

Deadline for manuscript submissions

closed (30 April 2024)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/190212

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).